As of 2024-12-13, the Relative Valuation of Arrowhead Pharmaceuticals Inc (ARWR) is (107.53) USD. This relative valuation is based on P/E multiples. With the latest stock price at 22.14 USD, the upside of Arrowhead Pharmaceuticals Inc based on Relative Valuation is -585.7%.
The range of the Relative Valuation is (104.45) - (117.18) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.7x - 28.9x | 22.3x |
| Forward P/E multiples | 20.1x - 24.3x | 22.3x |
| Fair Price | (104.45) - (117.18) | (107.53) |
| Upside | -571.8% - -629.3% | -585.7% |
| Date | P/E |
| 2024-12-13 | -4.53 |
| 2024-12-12 | -4.59 |
| 2024-12-11 | -4.71 |
| 2024-12-10 | -4.96 |
| 2024-12-09 | -4.83 |
| 2024-12-06 | -4.90 |
| 2024-12-05 | -4.62 |
| 2024-12-04 | -4.79 |
| 2024-12-03 | -5.41 |
| 2024-12-02 | -5.46 |
| 2024-11-29 | -5.40 |
| 2024-11-27 | -5.42 |
| 2024-11-26 | -4.37 |
| 2024-11-25 | -3.90 |
| 2024-11-22 | -3.84 |
| 2024-11-21 | -3.79 |
| 2024-11-20 | -3.88 |
| 2024-11-19 | -3.86 |
| 2024-11-18 | -3.94 |
| 2024-11-15 | -3.85 |
| 2024-11-14 | -4.44 |
| 2024-11-13 | -4.49 |
| 2024-11-12 | -4.46 |
| 2024-11-11 | -4.56 |
| 2024-11-08 | -4.54 |
| 2024-11-07 | -4.44 |
| 2024-11-06 | -4.43 |
| 2024-11-05 | -4.27 |
| 2024-11-04 | -4.16 |
| 2024-11-01 | -4.04 |
| 2024-10-31 | -3.99 |
| 2024-10-30 | -4.09 |
| 2024-10-29 | -4.14 |
| 2024-10-28 | -4.18 |
| 2024-10-25 | -4.17 |
| 2024-10-24 | -4.13 |
| 2024-10-23 | -4.13 |
| 2024-10-22 | -4.23 |
| 2024-10-21 | -4.25 |
| 2024-10-18 | -4.39 |
| 2024-10-17 | -4.32 |
| 2024-10-16 | -4.38 |
| 2024-10-15 | -4.12 |
| 2024-10-14 | -4.01 |
| 2024-10-11 | -3.82 |
| 2024-10-10 | -3.67 |
| 2024-10-09 | -3.70 |
| 2024-10-08 | -3.74 |
| 2024-10-07 | -3.76 |
| 2024-10-04 | -3.90 |